GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ESSA Pharma Inc (NAS:EPIX) » Definitions » Cash Flow from Investing

ESSA Pharma (ESSA Pharma) Cash Flow from Investing : $6.20 Mil (TTM As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is ESSA Pharma Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Dec. 2023, ESSA Pharma spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $60.99 Mil on purchasing investments. It gained $69.22 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it received $0.00 Mil from other investing activities. In all, ESSA Pharma gained $8.23 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2023.


ESSA Pharma Cash Flow from Investing Historical Data

The historical data trend for ESSA Pharma's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ESSA Pharma Cash Flow from Investing Chart

ESSA Pharma Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.20 -21.74 -35.02 -53.05 -3.53

ESSA Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.49 0.70 -2.47 -0.27 8.23

ESSA Pharma Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

ESSA Pharma's Cash Flow from Investing for the fiscal year that ended in Sep. 2023 is calculated as:

ESSA Pharma's Cash Flow from Investing for the quarter that ended in Dec. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ESSA Pharma  (NAS:EPIX) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

ESSA Pharma's purchase of property, plant, equipment for the three months ended in Dec. 2023 was $0.00 Mil. It means ESSA Pharma spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

ESSA Pharma's sale of property, plant, equipment for the three months ended in Dec. 2023 was $0.00 Mil. It means ESSA Pharma gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

ESSA Pharma's purchase of business for the three months ended in Dec. 2023 was $0.00 Mil. It means ESSA Pharma spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

ESSA Pharma's sale of business for the three months ended in Dec. 2023 was $0.00 Mil. It means ESSA Pharma gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

ESSA Pharma's purchase of investment for the three months ended in Dec. 2023 was $-60.99 Mil. It means ESSA Pharma spent {stock_data.stock.currency_symbol}}60.99 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

ESSA Pharma's sale of investment for the three months ended in Dec. 2023 was $69.22 Mil. It means ESSA Pharma gained $69.22 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

ESSA Pharma's net Intangibles purchase and sale for the three months ended in Dec. 2023 was $0.00 Mil. It means ESSA Pharma paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

ESSA Pharma's cash from discontinued investing activities for the three months ended in Dec. 2023 was 0.00 Mil. It means ESSA Pharma paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

ESSA Pharma's cash from other investing activities for the three months ended in Dec. 2023 was $0.00 Mil. It means ESSA Pharma received $0.00 Mil from other investing activities.


ESSA Pharma Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of ESSA Pharma's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


ESSA Pharma (ESSA Pharma) Business Description

Traded in Other Exchanges
N/A
Address
999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.
Executives
Peter Virsik officer: Chief Operating Officer 131 ESCANYO WAY, PORTOLA VALLEY CA 94028
David Ross Parkinson director, officer: Chief Executive Officer C/O THRESHOLD PHARMACEUTICALS, INC., 170 HARBOR WAY SUITE 300, SOUTH SAN FRANCISCO CA 94080
Franklin M Berger director 1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Lauren Merendino director C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
David S. Wood officer: Chief Financial Officer 3516 WEST 33RD AVE, VANCOUVER A1 V6N 2H4
Biotech Growth N V 10 percent owner ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Philip W. Kantoff director 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104